Vantage Consulting Group’s Pfizer PFE Stock Holding History

Vantage Consulting Group’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-8,463	Closed	-$237K	–	135
2024 Q2	$237K	Sell	8,463 -267	-3%	-$7.35K	0.18%	118
2024 Q1	$242K	Buy	8,730 +594	+7%	+$16.5K	0.15%	136
2023 Q4	$234K	Buy	8,136 +1,372	+20%	+$41.5K	0.16%	153
2023 Q3	$224K	Buy	6,764 +858	+15%	+$30.3K	0.15%	153
2023 Q2	$217K	Sell	5,906 -176	-3%	-$6.85K	0.12%	182
2023 Q1	$248K	Buy	6,082 +1,412	+30%	+$61K	0.14%	160
2022 Q4	$239K	Sell	4,670 -699	-13%	-$33.5K	0.14%	146
2022 Q3	$235K	Buy	5,369 +556	+12%	+$27K	0.14%	144
2022 Q2	$252K	Buy	4,813 +245	+5%	+$12.5K	0.14%	121
2022 Q1	$236K	Sell	4,568 -356	-7%	-$18.5K	0.09%	168
2021 Q4	$291K	Sell	4,924 -423	-8%	-$21K	0.08%	102
2021 Q3	$230K	Sell	5,347 -285	-5%	-$12.6K	0.05%	162
2021 Q2	$221K	Buy	+5,632	New	+$219K	0.04%	179
2021 Q1	–	Sell	-1,771	Closed	-$65K	–	1152
2020 Q4	$65K	Buy	+1,771	New	+$65K	0.01%	353

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return

Vantage Consulting Group's PFE Position: Q3 2024 in Review

Vantage Consulting Group sold out of Pfizer (PFE) in Q3 2024, closing a stake of 8,463 shares — an estimated $237K sold.

Vantage Consulting Group first reported a position in PFE in Q4 2020 and held it in 14 quarters. The position peaked at $291K in Q4 2021. 2,909 funds tracked by Wall St. Rank hold PFE as of Q3 2024.

Vantage Consulting Group reported no remaining Pfizer position as of Q3 2024 after selling out during the quarter.
Vantage Consulting Group sold 8,463 Pfizer shares in Q3 2024, an estimated $237K.
Vantage Consulting Group first reported a position in Pfizer in Q4 2020 and held it in 14 quarters.
Vantage Consulting Group's Pfizer position peaked at $291K in Q4 2021.
2,909 funds tracked by Wall St. Rank held Pfizer as of Q3 2024.

Based on Vantage Consulting Group's 13F filing for Q3 2024, filed 14 Nov 2024.